Dr. Bernard M. Agbemadzo, MD

Dr. Agbemadzo practices at Rust Pmg Cardiology - HOPD in Rio Rancho, New Mexico.

Dr. Agbemadzo's NPI, 1013940675, was assigned on July 8, 2006. Dr. Agbemadzo holds New Mexico license 2002-0192.

Dr. Agbemadzo's primary practice is Rust Pmg Cardiology - HOPD, at 2400 Unser Blvd SE, Rio Rancho, NM 87124.

Dr. Agbemadzo's primary practice is Rust Pmg Cardiology - HOPD in Rio Rancho, New Mexico. Dr. Agbemadzo is also affiliated with Presbyterian Hospital. The medical group on file is Presbyterian Medical Group. Dmand AI also links Dr. Agbemadzo to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Agbemadzo practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Agbemadzo's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Agbemadzo is licensed in New Mexico.

CMS data shows 615 Medicare services from Dr. Agbemadzo across 4 procedure codes in 2024, for 310 Medicare patients. Medicare paid $48,998 for them.

CMS counts 310 Medicare patients who saw Dr. Agbemadzo in 2024. The largest group is 65 to 74, with 138 patients. 60% of them have high blood pressure, and 59% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Agbemadzo's median patient age at 71, with 60% women.

In 2024, Dr. Agbemadzo wrote 1,962 Medicare Part D claims for 304 patients. 79% of them were for generic drugs. CMS names the drug for 1,620 of them, across 43 drugs with 11 or more claims each, at $2,499,742 in total drug cost. In 2023, CMS named 1,281 claims across 39 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Agbemadzo for performance year 2024, reported as part of a group. Dr. Agbemadzo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Agbemadzo as offering telehealth.

Dmand AI links Dr. Agbemadzo to 1 clinical trial. Conditions studied include Peripheral Nervous System Diseases and Ovarian Neoplasms.

CMS Open Payments shows 303 general payments to Dr. Agbemadzo from 36 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 90% of the total. Novartis Pharmaceuticals Corporation paid the most, $761.